复发性流产患者淋巴细胞免疫治疗的研究进展

doi:10.12280/gjfckx.20220746

摘要/Abstract

摘要：

复发性流产（recurrent spontaneous abortion，RSA）的发病率日益增加，已经成为当前困扰育龄期夫妻的严重问题。RSA的已知病因有染色体异常、宫腔疾病、内分泌异常和感染性因素等，但仍有50%的RSA病因不明，其中绝大多数与免疫因素有关，具体机制不明。目前已有免疫治疗，如淋巴细胞免疫治疗（lymphocytes immunotherapy，LIT），运用于封闭抗体阴性的患者，由于该治疗方法尚无统一的标准，故有些研究结果大相径庭，使得该治疗方法未能广泛推及。综述LIT的方法，拟为RSA的临床诊治提供依据，以期提高RSA患者的妊娠成功率。

关键词: 流产, 习惯性, 抗体, 封闭, 免疫疗法, 主动, 淋巴细胞, T淋巴细胞亚群, 杀伤细胞, 天然

Abstract:

The incidence of recurrent spontaneous abortion (RSA) is increasing, which has become a serious problem for couples of reproductive age. The etiology of RSA is known to include chromosomal abnormalities, intrauterine diseases, endocrine abnormalities, infectious factors, etc., but the cause of 50% of RSA is still unknown, most of which are related to immune factors, and the specific mechanism is unknown. At present, immunotherapy such as lymphocytes immunotherapy has been applied to patients with negative blocking antibodies. Due to the lack of uniform standards for this treatment, some studies have widely different results, which make this treatment method not widely applied. Therefore, this article reviews the treatment methods to provide a basis for the clinical diagnosis and treatment, in order to improve the success rate of pregnancy in RSA patients.

Key words: Abortion, habitual, Antibodies, blocking, Immunotherapy, active, Lymphocytes, T-lymphocyte subsets, Killer cells, natural

王瑞琪, 邓志敏, 代芳芳, 程艳香. 复发性流产患者淋巴细胞免疫治疗的研究进展[J]. 国际妇产科学杂志, 2023, 50(2): 138-141,160.

WANG Rui-qi, DENG Zhi-min, DAI Fang-fang, CHENG Yan-xiang. Research Progress of Lymphocytes Immunotherapy in Patients with Recurrent Spontaneous Abortion[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 138-141,160.

参考文献 36

[1]	Deng T, Liao X, Zhu S. Recent Advances in Treatment of Recurrent Spontaneous Abortion[J]. Obstet Gynecol Surv, 2022, 77(6):355-366. doi: 10.1097/OGX.0000000000001033. doi: 10.1097/OGX.0000000000001033 pmid: 35672876
[2]	Parhizkar F, Motavalli-Khiavi R, Aghebati-Maleki L, et al. The Impact of New Immunological Therapeutic Strategies on Recurrent Miscarriage and Recurrent Implantation Failure[J]. Immunol Lett, 2021, 236:20-30. doi: 10.1016/j.imlet.2021.05.008. doi: 10.1016/j.imlet.2021.05.008 pmid: 34090942
[3]	Sarkesh A, Sorkhabi AD, Ahmadi H, et al. Allogeneic lymphocytes immunotherapy in female infertility: Lessons learned and the road ahead[J]. Life Sci, 2022, 299:120503. doi: 10.1016/j.lfs.2022.120503. doi: 10.1016/j.lfs.2022.120503
[4]	Cavalcante MB, Sarno M, Barini R. Lymphocyte immunotherapy in recurrent miscarriage and recurrent implantation failure[J]. Am J Reprod Immunol, 2021, 85(4):e13408. doi: 10.1111/aji.13408. doi: 10.1111/aji.13408
[5]	Liu S, Gu X, Weng R. Clinical effect of lymphocyte immunotherapy on patients with unexplained recurrent spontaneous abortion[J]. Immun Inflamm Dis, 2021, 9(4):1272-1278. doi: 10.1002/iid3.474. doi: 10.1002/iid3.474
[6]	孙震. 主动免疫治疗对不明原因早期复发性自然流产患者妊娠结局的影响[J]. 中国现代药物应用, 2021, 15(24):70-72. doi: 10.14164/j.cnki.cn11-5581/r.2021.24.026. doi: 10.14164/j.cnki.cn11-5581/r.2021.24.026
[7]	王会敏, 李春, 王丹, 等. 血清维生素D、sPD-L1及HCG与复发性流产主动免疫治疗预后的关系研究[J]. 国际检验医学杂志, 2020, 41(18):2268-2271. doi: 10.3969/j.issn.1673-4130.2020.18.022. doi: 10.3969/j.issn.1673-4130.2020.18.022
[8]	Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion[J]. Fertil Steril, 2012, 98(5):1103-1111. doi: 10.1016/j.fertnstert.2012.06.048. doi: 10.1016/j.fertnstert.2012.06.048 pmid: 22835448
[9]	Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage[J]. Cochrane Database Syst Rev, 2014(10): CD000112. doi: 10.1002/14651858.CD000112.pub3. doi: 10.1002/14651858.CD000112.pub3
[10]	ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss[J]. Hum Reprod Open, 2018, 2018(2):hoy004. doi: 10.1093/hropen/hoy004. doi: 10.1093/hropen/hoy004
[11]	Cavalcante MB, Sarno M, Araujo Júnior E, et al. Lymphocyte immunotherapy in the treatment of recurrent miscarriage: systematic review and meta-analysis[J]. Arch Gynecol Obstet, 2017, 295(2):511-518. doi: 10.1007/s00404-016-4270-z. doi: 10.1007/s00404-016-4270-z pmid: 28004193
[12]	Sarno M, Cavalcante MB, Niag M, et al. Gestational and perinatal outcomes in recurrent miscarriages couples treated with lymphocyte immunotherapy[J]. Eur J Obstet Gynecol Reprod Biol X, 2019, 3:100036. doi: 10.1016/j.eurox.2019.100036. doi: 10.1016/j.eurox.2019.100036
[13]	刘小立. 淋巴细胞主动免疫疗法治疗封闭抗体阴性复发性流产患者的效果[J]. 中国民康医学, 2022, 34(10):58-61. doi: 10.3969/j.issn.1672-0369.2022.10.018. doi: 10.3969/j.issn.1672-0369.2022.10.018
[14]	张华坤, 刘庆芝, 谢建生, 等. 封闭抗体缺失与不同类型复发性自然流产关系分析[J]. 实用妇产科杂志, 2015, 31(10):787-789.
[15]	史晓艳, 陈铭, 石玉玲. 淋巴细胞主动免疫治疗对封闭抗体阴性复发性流产后患者外周血Th1/Th2/Th17细胞因子表达水平变化[J]. 陕西医学杂志, 2017, 46(10):1407-1409. doi: 10.3969/j.issn.1000-7377.2017.10.036. doi: 10.3969/j.issn.1000-7377.2017.10.036
[16]	丁桂春, 陈灿明, 沈桂红. 主动免疫治疗封闭抗体阴性复发性流产的临床观察[J]. 中国计划生育学杂志, 2018, 26(8):743-744. doi: 10.3969/j.issn.1004-8189.2018.08.026. doi: 10.3969/j.issn.1004-8189.2018.08.026
[17]	Yuan J, Li J, Huang SY, et al. Characterization of the subsets of human NKT-like cells and the expression of Th1/Th2 cytokines in patients with unexplained recurrent spontaneous abortion[J]. J Reprod Immunol, 2015, 110:81-88. doi: 10.1016/j.jri.2015.05.001. doi: 10.1016/j.jri.2015.05.001 pmid: 26057526
[18]	王红宇, 李明珠. Th1/Th2型细胞因子与原因不明复发性流产的相关性研究[J]. 实用医药杂志, 2017, 34(3):213-214,217. doi: 10.14172/j.issn1671-4008.2017.03.008. doi: 10.14172/j.issn1671-4008.2017.03.008
[19]	Liu M, Zhen X, Song H, et al. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage[J]. Reprod Biol Endocrinol, 2017, 15(1):95. doi: 10.1186/s12958-017-0315-9. doi: 10.1186/s12958-017-0315-9
[20]	常兴隆. 复发性流产患者Th1/Th2型细胞因子的表达分析[J]. 数理医药学杂志, 2021, 34(1):45-46. doi: 10.3969/j.issn.1004-4337.2021.01.018. doi: 10.3969/j.issn.1004-4337.2021.01.018
[21]	Ji J, Zhai H, Zhou H, et al. The role and mechanism of vitamin D-mediated regulation of Treg/Th17 balance in recurrent pregnancy loss[J]. Am J Reprod Immunol, 2019, 81(6):e13112. doi: 10.1111/aji.13112. doi: 10.1111/aji.13112
[22]	Chang S, Yin T, He F, et al. CaMK4 promotes abortion-related Th17 cell imbalance by activating AKT/mTOR signaling pathway[J]. Am J Reprod Immunol, 2020, 84(6):e13315. doi: 10.1111/aji.13315. doi: 10.1111/aji.13315
[23]	张玉萍, 燕美琴, 王丽萍, 等. 辅助性T细胞17和调节性T细胞相关细胞因子在不明原因复发性流产中的变化及意义[J]. 中国药物与临床, 2019, 19(8):1273-1275. doi: 10.11655/zgywylc2019.08.023. doi: 10.11655/zgywylc2019.08.023
[24]	Li N, Qu Q, Yan Q. The role of Th17/Treg-mediated immunoregulation in abortion mice[J]. Eur J Inflamm, 2018, 16:2058739218760354. doi: 10.1177/2058739218760354. doi: 10.1177/2058739218760354
[25]	Wu L, Luo LH, Zhang YX, et al. Alteration of Th17 and Treg cells in patients with unexplained recurrent spontaneous abortion before and after lymphocyte immunization therapy[J]. Reprod Biol Endocrinol, 2014, 12:74. doi: 10.1186/1477-7827-12-74. doi: 10.1186/1477-7827-12-74
[26]	张小玲, 王娟. 淋巴细胞主动免疫治疗对原因不明性复发性流产患者Treg及Th17细胞因子的影响[J]. 贵州医药, 2020, 44(10):1548-1549. doi: 10.3969/j.issn.1000-744X.2020.10.013. doi: 10.3969/j.issn.1000-744X.2020.10.013
[27]	张维平, 王文文, 张调平, 等. 主动免疫治疗对原因不明性复发性流产患者Treg/Th17免疫平衡的影响[J]. 中国妇产科临床杂志, 2021, 22(3):249-251. doi: 10.13390/j.issn.1672-1861.2021.03.009. doi: 10.13390/j.issn.1672-1861.2021.03.009
[28]	Pan D, Liu Q, Du L, et al. Polarization disorder of decidual NK cells in unexplained recurrent spontaneous abortion revealed by single-cell transcriptome analysis[J]. Reprod Biol Endocrinol, 2022, 20(1):108. doi: 10.1186/s12958-022-00980-9. doi: 10.1186/s12958-022-00980-9
[29]	王和坤, 梁宝珠, 黄显文, 等. NK细胞在不明原因复发性流产诊治研究中的意义[J]. 黑龙江医学, 2015, 39(6):600-601. doi: 10.3969/j.issn.1004-5775.2015.06.003. doi: 10.3969/j.issn.1004-5775.2015.06.003
[30]	赵花, 韦相才, 钟兴明, 等. 复发性流产患者主动免疫治疗后淋巴细胞免疫表型的变化[J]. 生殖医学杂志, 2014, 23(6):453-457. doi: 10.3969/j.issn.1004-3845.2014.06.005. doi: 10.3969/j.issn.1004-3845.2014.06.005
[31]	自然流产诊治中国专家共识编写组. 自然流产诊治中国专家共识(2020年版)[J]. 中国实用妇科与产科杂志, 2020, 36(11):1082-1090. doi: 10.19538/j.fk2020110113. doi: 10.19538/j.fk2020110113
[32]	Eidizadeh A, Papert S, Valk J, et al. Adverse drug reactions following lymphocyte immunotherapy for the treatment of infertility: A retrospective study[J]. J Obstet Gynaecol Res, 2022, 48(10):2571-2582. doi: 10.1111/jog.15348. doi: 10.1111/jog.15348
[33]	Kling C, Steinmann J, Westphal E, et al. Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity[J]. Hum Reprod, 2006, 21(2):429-435. doi: 10.1093/humrep/dei316. doi: 10.1093/humrep/dei316 pmid: 16210388
[34]	Kling C, Steinmann J, Flesch B, et al. Transfusion-related risks of intradermal allogeneic lymphocyte immunotherapy: single cases in a large cohort and review of the literature[J]. Am J Reprod Immunol, 2006, 56(3):157-171. doi: 10.1111/j.1600-0897.2006.00413.x. doi: 10.1111/j.1600-0897.2006.00413.x pmid: 16911711
[35]	Pan X, Jiang J, Ma Q, et al. Outbreak of HIV Infection Linked to Nosocomial Transmission, China, 2016-2017[J]. Emerg Infect Dis, 2018, 24(12):2141-2149. doi: 10.3201/eid2412.180117. doi: 10.3201/eid2412.180117 pmid: 30457542
[36]	王辰焱, 徐静波, 蔡贤君, 等. 早期免疫治疗对不明原因复发性流产患者IL-2和IL-10水平的影响[J]. 中国妇幼保健, 2021, 36(21):4983-4985. doi: 10.19829/j.zgfybj.issn.1001-4411.2021.21.031. doi: 10.19829/j.zgfybj.issn.1001-4411.2021.21.031